Jilu Zhang, PhD
My research is focused on implementing and optimizing advanced technology platforms, especially flow cytometry, mass cytometry (CyTOF) and imaging mass cytometry (IMC), to enable analyses of the complexity and heterogeneity of the immune system. By taking advantage of those cutting-edge immune-monitoring technology, I am interested in developing innovative approaches to evaluate immune responses and new biomarkers / immunotherapies for diverse clinical conditions such as Inflammatory disease, autoimmune disease and cancer. In my PhD research program, I worked on the discovering therapeutic targets for Graft-versus-host disease (GVHD) by utilizing multiple immune-related technology platforms. To broaden my research experience and acquire more professional training, I had postdoctoral trainings at the Indiana University and Icahn School of Medicine at Mount Sinai. In 2017, I joined the Houston Methodist Research Institute to continue my research focused on developing new immune monitoring assays for human disease, and as immune assessment core manager for the immune functional assay through flow cytometry, CyTOF, IMC and other immune monitoring assays.